Valuation — not yet established
No valuation for Kinnate Biopharma is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($98.0M) and the funding record below are the closest available signals.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
See the evidence behind this price
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Kinnate Biopharma
Create free account
No card required
Funding history
2 rounds| Date | Round | Raised | Post-money | $/share |
|---|---|---|---|---|
| Aug 2020 | Later Stage VC (Series C) | $98.0M | ▮ | ▮ |
| Dec 2019 | Later Stage VC | $74.5M | ▮ | ▮ |
How Kinnate Biopharma's valuation is determined
Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.
For Kinnate Biopharma, too few pricing signals exist to publish a composite mark; the figures above reflect the most recent observed valuation event. Full methodology →
Frequently asked
- How much has Kinnate Biopharma raised?
- Kinnate Biopharma has raised $98.0M in total funding across 2 recorded rounds.
- When did Kinnate Biopharma last raise?
- Kinnate Biopharma last raised in Aug 2020 (Later Stage VC (Series C)), raising $98.0M.